Pediatric Clinics of North America - CIPERJ

482 KWIATKOWSKI
[77] Tondury P, Zimmerman A, Nielsen P, et al. Liver iron and fibrosis during long-term
treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 1998;101(3):413–5.
[78] Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during longterm
therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia.
Blood 2002;100(5):1566–9.
[79] Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in
thalassemia major. Haematologica 2005;90(10):1309–14.
[80] Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapy
with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis 2006;36(1):21–5.
[81] Breuer W, Ermers MJJ, Pootrakul P, et al. Desferrioxamine-chelatable iron, a component of
serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 2001;97(3):
792–8.
[82] Link G, Konijn AM, Breuer W, et al. Exploring the ‘‘iron shuttle’’ hypothesis in chelation
therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused
rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med
2001;138(2):130–8.
[83] Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind
trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial
iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;
115(14):1876–84.
[84] Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670,
a new orally active iron-chelating agent in patients with transfusion-dependent iron overload
due to beta-thalassemia. J Clin Pharmacol 2003;43(6):565–72.
[85] Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in
iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled,
dose-escalation trial. Lancet 2003;361(9369):1597–602.
[86] Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes
and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-year prospective
study. Eur J Haematol 2008;80(2):168–76.
[87] Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation
therapy in beta-thalassemia major. Blood 2008;111(2):583–7.
[88] Glickstein H, El RB, Link G, et al. Action of chelators in iron-loaded cardiac cells: Accessibility
to intracellular labile iron and functional consequences. Blood 2006;108(9):3195–203.
[89] Wood JC, Otto-Duessel M, Gonzalez I, et al. Deferasirox and deferiprone remove cardiac
iron in the iron-overloaded gerbil. Transl Res 2006;148(5):272–80.
[90] Porter JB, Tanner MA, Pennell DJ, et al. Improved myocardial T2* in transfusion dependent
anemias receiving ICL670 (deferasirox). Blood 2005;106(11):1003a.
[91] Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported
outcomes during treatment with deferasirox or deferoxamine for iron overload in patients
with beta-thalassemia. Clin Ther 2007;29(5):909–17.
[92] Barton JC. Drug evaluation: Deferitrin for iron overload disorders. IDrugs 2007;10(7):
480–90.
[93] Donovan JM, Yardumian A, Gunawardena KA, et al. The safety and pharmacokinetics of
deferitrin, a novel orally available iron chelator. Blood 2004;104(11):146a.
[94] Link G, Ponka P, Konijn AM, et al. Effects of combined chelation treatment with pyridoxal
isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in ironloaded
rat heart cells. Blood 2003;101(10):4172–9.
[95] Brittenham GM. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral
administration. Semin Hematol 1990;27(2):112–6.
[96] Cohen AR, Galanello R, Pennell DJ, et al. Thalassemia. Hematology Am Soc Hematol Educ
Program 2004;14–34.
[97] Vichinsky E. Consensus document for transfusion-related iron overload. Semin Hematol
2001;38(Suppl 1):2–4.